250 related articles for article (PubMed ID: 21763367)
1. Recent advances and novel strategies in pre-clinical formulation development: an overview.
Shah AK; Agnihotri SA
J Control Release; 2011 Dec; 156(3):281-96. PubMed ID: 21763367
[TBL] [Abstract][Full Text] [Related]
2. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
Mishra V; Gupta U; Jain NK
Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
[TBL] [Abstract][Full Text] [Related]
3. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in intravenous delivery of poorly water-soluble compounds.
Shi Y; Porter W; Merdan T; Li LC
Expert Opin Drug Deliv; 2009 Dec; 6(12):1261-82. PubMed ID: 19941409
[TBL] [Abstract][Full Text] [Related]
5. In vitro - in vivo correlation: from theory to applications.
Emami J
J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
[TBL] [Abstract][Full Text] [Related]
6. Developing early formulations: practice and perspective.
Li P; Zhao L
Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
[TBL] [Abstract][Full Text] [Related]
7. An integrated early formulation strategy--from hit evaluation to preclinical candidate profiling.
Maas J; Kamm W; Hauck G
Eur J Pharm Biopharm; 2007 Apr; 66(1):1-10. PubMed ID: 17123801
[TBL] [Abstract][Full Text] [Related]
8. Oral formulation strategies to improve solubility of poorly water-soluble drugs.
Singh A; Worku ZA; Van den Mooter G
Expert Opin Drug Deliv; 2011 Oct; 8(10):1361-78. PubMed ID: 21810062
[TBL] [Abstract][Full Text] [Related]
9. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. Preclinical formulations for discovery and toxicology: physicochemical challenges.
Neervannan S
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):715-31. PubMed ID: 17014391
[TBL] [Abstract][Full Text] [Related]
12. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
O'Driscoll CM; Griffin BT
Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
[TBL] [Abstract][Full Text] [Related]
13. Strategic use of preparative chiral chromatography for the synthesis of a preclinical pharmaceutical candidate.
Leonard WR; Henderson DW; Miller RA; Spencer GA; Sudah OS; Biba M; Welch CJ
Chirality; 2007 Sep; 19(9):693-700. PubMed ID: 17354260
[TBL] [Abstract][Full Text] [Related]
14. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
15. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
Buckley LA; Dorato MA
Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
[TBL] [Abstract][Full Text] [Related]
16. Preclinical formulations: insight, strategies, and practical considerations.
Shah SM; Jain AS; Kaushik R; Nagarsenker MS; Nerurkar MJ
AAPS PharmSciTech; 2014 Oct; 15(5):1307-23. PubMed ID: 24920522
[TBL] [Abstract][Full Text] [Related]
17. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
18. Metal complexes in medicinal chemistry: new vistas and challenges in drug design.
Thompson KH; Orvig C
Dalton Trans; 2006 Feb; (6):761-4. PubMed ID: 16437168
[TBL] [Abstract][Full Text] [Related]
19. Diverse approaches for the enhancement of oral drug bioavailability.
Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
[TBL] [Abstract][Full Text] [Related]
20. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies.
Pouton CW; Porter CJ
Adv Drug Deliv Rev; 2008 Mar; 60(6):625-37. PubMed ID: 18068260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
